Molina J A, Jiménez-Jiménez F J, Navarro J A, Ruiz E, Arenas J, Cabrera-Valdivia F, Vázquez A, Fernández-Calle P, Ayuso-Peralta L, Rabasa M
Department of Neurology, Hospital Doce de Octubre, Madrid, Spain.
J Neurol Sci. 1994 Dec 1;127(1):87-89. doi: 10.1016/0022-510x(94)90139-2.
It has been suggested that nitric oxide (NO) could be implicated in the neuronal degeneration of substantia nigra compacta in patients with Parkinson's disease (PD). To ascertain the possible role of NO as risk factor for PD, we studied the plasma levels of nitrate (oxidation product that provides an indirect estimation of NO), in 68 PD patients and 68 matched-controls. The plasma levels of nitrate did not differ significantly between PD patient and control groups (44.5 +/- 2.46 and 44.8 +/- 2.67 mumol/l, respectively). They were not influenced by antiparkinsonian drug and they did not correlate with age at onset, duration, scores of the Unified Parkinson's Disease Rating scales and Hoehn and Yahr staging in the PD group. These data suggest that plasma levels of nitrate are apparently unrelated to the risk for PD.
有人提出，一氧化氮（NO）可能与帕金森病（PD）患者黑质致密部的神经元变性有关。为了确定NO作为PD风险因素的可能作用，我们研究了68例PD患者和68例匹配对照者的血浆硝酸盐水平（硝酸盐是一种氧化产物，可间接估计NO水平）。PD患者组和对照组的血浆硝酸盐水平无显著差异（分别为44.5±2.46和44.8±2.67μmol/L）。它们不受抗帕金森病药物的影响，且与PD组的发病年龄、病程、统一帕金森病评定量表评分以及Hoehn和Yahr分期均无相关性。这些数据表明，血浆硝酸盐水平显然与PD风险无关。
